We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medgenics | MEDU | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 392.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 392.50 | 392.50 |
| Top Posts |
|---|
Posted at 21/2/2014 09:45 by 237gmoney Medgenics looks to accelerate gene therapy platform after transition yearThu 10:05 am by Giles Gwinnett The company reported a net loss of US$17.13 million for the year ended December 31 last year compared with a net loss of $15.07 million in 2012 Medgenics (LON:MEDG, NYSE:MDGN) plans to accelerate its gene therapy platform and maximise the potential of its technology assets, it told investors, unveiling 2013 financial results. The firm is developing Biopump to treat patients and last year repositioned itself as a rare and orphan disease firm with a brand new executive management team. Michael Cola, president and chief exexcutive, told the statement: "2013 has been an important transition year for us as we build a foundation and corporate strategy to position the company for the future. "Based on results to date, we've developed a second generation viral vector and Biopump protocol that shows more durable protein production in SCID mice, a model historically predictive of success in human clinical trials. "We plan to utilise this new vector and protocol as we realign our research and development focus towards the orphan and rare disease market, where we feel the Biopump's attributes of continuous autologous protein/peptide production would be highly advantageous." Cola said the company had two aims for 2014 - firstly to begin the Phase 1/2 EPODURE trial for human proof-of-concept of the Biopump platform with the second-generation viral vector and protocol, and to replicate the mouse results in humans. Secondly, the company wants to obtain in-vitro (test tube) and in-vivo (living) preclinical data in human tummy-tuck tissue and mice in several rare and orphan disease indications. The company reported a net loss of US$17.13 million for the year ended December 31 last year compared with a net loss of $15.07 million in 2012. |
Posted at 13/2/2014 12:40 by 237gmoney Thanks, I do look in from time to time at IMM. Interesting company. Will keep watching it for now.I currently hold stock in a Bangladesh pharma - Beximco Pharma - Ticker in London BXP.L. The share price is materially below the Stock price equivalent in Dhaka at the moment. Hopefully that will correct itself soon as that is a growing company and a few new investors have moved in there over the last few months. For Medgenics I found the Institutional holders have expanded in recent months as well - Vanguard, Belmont, B Gifford and Bridgeway are all buying stock. No wonder the stock is rising in the US if this continues. L&G have increased their holding by over 200k shares since yr end. |
Posted at 04/11/2013 16:50 by pdt I see that there is an investor conference call on Friday. Hopefully there may be hint of business strategy from the new management team, it would be good if they could find some joint venture partners and prove that other big pharma endorse the technology.I have recently sold a good part of my holding and bought more Immupharma (IMM) since I think there will be positive news on that one over the next month or two. So I actually hope there is not too much progress to report on Friday! |
Posted at 22/9/2013 18:08 by 237gmoney hxxp://seekingalpha.Investors in the biotechnology sector probably don't need any antidepressants. Many biotechnology stocks are namely among the best performing across the stock market. Over the last 5 years, the biotechnology index trackers tripled in price. But did all biotechnology companies flourish? We discovered a small company that Wall Street has forgotten about but in fact is well positioned to become one of the greatest developers of medical technology that allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases such as anemia and hepatitis C. The industry in which they operate is worth billions of dollars. The company is Medgenics (MDGN) and this article explains why this stock is a must have for investors who are searching for a highly skewed risk/reward investment. Company overview Medgenics was founded in 2000 in San Francisco as a medical technology and therapeutics company which engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump, a groundbreaking tissue-based platform technology for the production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases, including anemia, hepatitis, hemophilia, and other chronic diseases. This pump technology is a platform for endless indications. Therefore the company plans to develop a pipeline of products based on this technology to target the broader large and rapidly growing global protein therapy market. R&D and manufacturing operates in Misgav, Israel and U.S. manufacturing operates in San Francisco. |
Posted at 14/4/2013 21:02 by 237gmoney Equities research analysts at Roth Capital started coverage on shares of Medgenics (NASDAQ: MDGN) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a "buy" rating and a $13.00 price target on the stock.Medgenics (NASDAQ: MDGN) opened at 4.379 on Wednesday. Medgenics has a 1-year low of $4.21 and a 1-year high of $16.43. The stock's 50-day moving average is currently $4.86. The company's market cap is $53.5 million. |
Posted at 26/3/2013 13:55 by 237gmoney The problem the company have is that they are not well known to potential investors, especially in the UK and Europe and presentations like the Roth Conference will help boost awareness. At the moment there is only a select few investors in the stock out there.The Maxim growth conference which the company attended last year on 21st March is not scheduled to happen until around September time this year in New York. There are a few conferences coming up which should be on the Radar for the Company to present at including the BoA Merril Lynch conference in Boston on 7-8th May or the Baird Growth Conference in Chicago on 7-9th May. UBS are lining up a conference in July for small/mid caps in New York but that is maybe something to think about further down the line. Still some good news today. |
Posted at 14/7/2012 12:04 by jammytass Wall Street All-Star analyst Sharon di Stefano, a long-time observer of Barer's career who watched him build that company into a multi-billion dollar biotech powerhouse, recognized the latest development at Medgenics. In her recent article, she cites the power the company and its main investors have shown to attract Barer, one of the most respected scientific and business figures in the last 25 years. We've known and worked with Ms. di Stefano for many years and have collaborated on ideas that have made investors millions of dollars. We agree with her and also expect good things to happen at Medgenics with Dr. Barer and the helm. Indisputable is the fact that the team behind Medgenics has a history of infusing fledgling life science companies with both monetary and intellectual capital.We are not alone in our enthusiasm for the firm and believe the cost-effectiveness of MDGN's products all point to significant future shares in multiple sizeable markets. |
Posted at 27/6/2012 08:42 by kalinit SueYou1 and britishb - Gents or Ladies - forgive me but this was a fairly serious forum for serious investors who may/maynot be about to make life changing amounts of money (only time will tell).Posts by Sicilian Khan (see key early research which started this thread) are amongst the best research and balanced comment you will ever find on a BB. Please let us continue to use this BB for what it was designed for, and take your personal feud to another forum, as some of us put a lot of time and effort into what is posted,find it a very useful tool and pay close attention to what is written. It is hard to follow the train of thought, comments and genuine questions when you are both arguing in the way you do. |
Posted at 26/6/2012 09:51 by britishb Sadly Sue, as I have pointed out repeatedly, you are IMVHO utterly clueless. Your numbers are utter drivel. There are MEDU and MEDG shares as well as MDGN in the US. Market cap is way higher than you suggest.Did you read the thread header? "At the ProActive presentation on 23 June 2011, the Medgenics' CEO Andy Pearlman stated that Isaac Blech believes that Medgenics could become the next Genentech. Isaac Blech has founded 7 biotech companies that now have a combined value of more than $30bn. Isaac Blech is one of the leading biotechnology entrepreneurs and investors in the US. He has now bought 17.5% of Medgenics and has just been appointed to the board of directors." So, one of the world's leading biotech investors bought 17.5% of the company. Genentech, just for your info, was sold to Roche for $46.8 billion. Tell me, just how many more times are you going to embarrass yourself? |
Posted at 19/6/2012 20:40 by jammytass get ready for lift off !!!! £7.00 end of july £10+ = year endMISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jun. 19, 2012-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of a novel Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced it has raised gross proceeds of approximately $9.5 million (approximately $8.4 million net) through the sale of 1,944,734 units (the "Units"), with each Unit consisting of one share of the Company's Common Stock, $0.0001 par value per share (the "Common Stock"), and a warrant to purchase 0.75 of one share of Common Stock (the "Warrants"). Each Unit was sold for a purchase price of $4.90 to institutional and other accredited investors in a private placement transaction. The Warrants expire in five years, have an initial exercise price of $8.34 per full share and become first exercisable on December 15, 2012. Medgenics intends to use the proceeds from this private placement to further its clinical trial programs for its EPODURE Biopump producing erythropoietin for the treatment of anemia, and its INFRADURE Biopump producing interferon-alpha for the treatment of hepatitis, as well as for other research and development, patent maintenance and other intellectual property support and general corporate purposes. The Units, including the Common Stock and the Warrants constituting the Units, and the shares of Common Stock issuable upon the exercise of the Warrants have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold absent registration or an applicable exemption from registration. Medgenics has agreed to cause the resale of the Common Stock issued as part of the Units and the shares of Common Stock issuable upon the exercise of the Warrants to be registered for resale with the U.S. Securities and Exchange Commission. Maxim Group LLC acted as the exclusive placement agent for the private placement. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
